Streetbeat News

Products Services

INO

INOVIO reported its Q3 2024 financial results and highlighted recent business developments, including promising immunology data for INO-3107. The data showed INO-3107's ability to induce a cytotoxic T cell response against HPV-6 and HPV-11, potentially reducing surgeries for RRP patients. Regulatory submissions for INO-3107 are on track, with a BLA submission targeted for mid-2025.

Portfolio Pulse from

November 14, 2024 | 9:15 pm

AEM

AEM stock has experienced a 39% year-to-date price rally, supported by a strong pipeline of growth projects, solid financial health, favorable gold pricing, and a healthy growth trajectory.

Portfolio Pulse from

November 14, 2024 | 9:15 pm

SLNO

Soleno Therapeutics will present data on its DCCR tablets for Prader-Willi syndrome at the ESPE 2024 meeting, potentially impacting its stock.

Portfolio Pulse from

November 14, 2024 | 9:15 pm

FFNTF

4Front Ventures Corp. reported Q3 2024 results with $17.1 million in revenue and $1.0 million in adjusted EBITDA. The company is nearing full operational capacity at its Matteson facility in Illinois, which is expected to drive growth. Massachusetts wholesale saw over 56% growth, and Washington facilities returned to revenue highs.

Portfolio Pulse from

November 14, 2024 | 9:15 pm

CRNX

Crinetics Pharmaceuticals is set to present its advancements in neuroendocrine tumor treatments at the NANETS Annual Meeting. The company will debut its novel nonpeptide drug conjugate platform, highlighting the preclinical profile of its lead candidate CRN09682, which targets SST2-expressing tumors and is expected to submit an IND by early 2025.

Portfolio Pulse from

November 14, 2024 | 9:15 pm

SMID

Smith-Midland Corporation (NASDAQ:SMID) reported a record quarterly revenue of $23.6 million for Q3 2024, a 51% increase from the previous year. The company saw a significant rise in service revenue and net income, driven by sector tailwinds and special barrier projects.

Portfolio Pulse from

November 14, 2024 | 9:15 pm

DARE

Daré Bioscience reported its Q3 2024 financial results and provided updates on its development programs. Key highlights include progress in the Ovaprene® contraceptive study, Sildenafil Cream for female sexual arousal disorder, and other products in various stages of clinical trials. The company has received significant funding to support these initiatives.

Portfolio Pulse from

November 14, 2024 | 9:15 pm

BSKY

BluSky Carbon is advancing its technology to remove CO2 from the atmosphere, aiming to store carbon for thousands of years while producing low-cost energy. The company sees carbon removal as a significant future business opportunity.

Portfolio Pulse from

November 14, 2024 | 9:00 pm

DEXC

Dimensional has launched its 41st U.S.-listed ETF, the Dimensional Emerging Markets ex China Core Equity ETF (DEXC), which focuses on emerging markets excluding China. It is listed on the NYSE Arca with an expense ratio of 0.43%.

Portfolio Pulse from

November 14, 2024 | 8:45 pm